AllianceRx Walgreens Prime Study Comparing Digital and Telephonic Patients Shows Similar Adherence
Retrieved on:
Thursday, February 3, 2022
Degenerative disease, Patient, Pharmacy, PDC, Patient satisfaction, Research, MS, Population, Cancer, Cystic fibrosis, Health, CSP, Miller, Idiopathic pulmonary fibrosis, Pharmacist, Baloch people, MBA, Multiple sclerosis, Walgreens, Mark (given name), Prescription, Pharmaceutical industry, Medicine, Healthcare
Proprietary algorithms use the patient-reported responses to identify patients who require additional support from pharmacists, who then consult with the patient.
Key Points:
- Proprietary algorithms use the patient-reported responses to identify patients who require additional support from pharmacists, who then consult with the patient.
- Today, in addition to MS, digital clinical assessments are available for patients with chronic inflammatory disease, cystic fibrosis, idiopathic pulmonary fibrosis, organ transplants, lipid and blood disorders, and cancer.
- Sabeen Hasni, RPh , director of pharmacy quality at AllianceRx Walgreens Prime and a lead researcher of the study, said the research team wanted to gauge the impact of digital clinical assessments on outcomes and the patient experience.
- Hasni said adherence, as measured by PDC, was statistically higher across almost all MS therapies included in the study.